\
&
Contact us
\
&
Contact us
Overseas territories are linked to one of the European Member States and are therefore eligible to receive funding from Horizon Europe. Participants from overseas territories can participate in all parts of Horizon Europe on the same terms as entitites from the EU Member States.
N/A
All details regarding country eligibility is compiled in the infosheet “International cooperation".
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
